A biomimetic peptide recognizes and traps bacteria in vivo as human defensin-6

Sci Adv. 2020 May 8;6(19):eaaz4767. doi: 10.1126/sciadv.aaz4767. eCollection 2020 May.

Abstract

Using broad-spectrum antibiotics for microbial infection may cause flora disequilibrium, drug-resistance, etc., seriously threatening human health. Here, we design a human defensin-6 mimic peptide (HDMP) that inhibits bacterial invasion in vivo through mimicking the mechanisms of human defensin-6 with high efficiency and precision. The HDMP with ligand and self-assembling peptide sequence recognizes bacteria through ligand-receptor interactions and subsequently traps bacteria by an in situ adaptive self-assembly process and resulting nanofibrous networks; these trapped bacteria are unable to invade host cells. In four animal infection models, the infection rate was markedly decreased. Notably, administration of HDMP (5 mg/kg) nanoparticles increased the survival rate of mice with methicillin-resistant S. aureus bacteremia by as much as 100%, even more than that of vancomycin treatment (5 mg/kg, 83.3%)-treated group, the golden standard of antibiotics. This biomimetic peptide shows great potential as a precise and highly efficient antimicrobial agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Bacteria
  • Biomimetics
  • Defensins / pharmacology
  • Humans
  • Ligands
  • Methicillin-Resistant Staphylococcus aureus*
  • Mice
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Defensins
  • Ligands
  • Vancomycin